Lorenza Sisinni

Lorenza Sisinni

Auto-generated profile, based on publicly available information

Lorenza Sisinni

Laboratory of Pre-Clinical and Translational Research, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Pz, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GRGiuseppe La Regina
Giuseppe La Regina
RBRuoli Bai
Ruoli Bai
ACAntonio Coluccia
Antonio Coluccia
VFValeria Famiglini
Valeria Famiglini
SPSveva Pelliccia
Sveva Pelliccia
RSRomano Silvestri
Romano Silvestri

2 May 2013 in Molecular Oncology
Verified
Journal Article
Open access
FMFrancesca Maddalena
Francesca Maddalena
LSLorenza Sisinni
Lorenza Sisinni
GLGiacomo Lettini
Giacomo Lettini
VCValentina Condelli
Valentina Condelli
DMDanilo Swann Matassa
Danilo Swann Matassa
MLMatteo Landriscina
Matteo Landriscina
TRAP1 is a mitochondrial antiapoptotic protein up‐regulated in several human malignancies. However, recent evidences suggest that TRAP1 is also localized in the endoplasmic reticulum (ER) where it is involved in ER stress protection and protein quality control of tumor cells. Based on the mechanistic link between ER stress, protection from apoptosis and drug resistance, we questioned whether these novel roles of TRAP1 are relevant for its antiapoptotic function. Here, we show for the first time that: i) TRAP1 expression is increased in about 50% of human breast carcinomas (BC), and ii) the ER stress protecting activity of TRAP1 is conserved in human tumors since TRAP1 is co‐upregulated with the ER stress marker, BiP/Grp78. Notably, ER‐associated TRAP1 modulates mitochondrial apoptosis by exerting a quality control on 18 kDa Sorcin, a TRAP1 mitochondrial client protein involved in TRAP1 cytoprotective pathway. Furthermore, this TRAP1 function is relevant in favoring resistance to paclitaxel, a microtubule stabilizing/ER stress inducer agent widely used in BC therapy. Indeed, the transfection of a TRAP1 deletion mutant, whose localization is restricted to the ER, in shTRAP1 cells enhances the expression of mitochondrial Sorcin and protects from apoptosis induced by ER stress agents and paclitaxel. Furthermore, BC cells adapted to paclitaxel or ER stress inducers share common resistance mechanisms: both cell models exhibit cross‐resistance to single agents and the inhibition of TRAP1 by siRNAs or gamitrinib, a mitochondria‐directed HSP90 family inhibitor, in paclitaxel‐resistant cells rescues the sensitivity to paclitaxel. These results support the hypothesis that ER‐associated TRAP1 is responsible for an extramitochondrial control of apoptosis and, therefore, an interference of ER stress adaptation through TRAP1 inhibition outside of mitochondria may be considered a further compartment‐specific molecular approach to rescue drug‐resistance.

10 October 2013 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
DMDanilo Swann Matassa
Danilo Swann Matassa
MAM R Amoroso
M R Amoroso
IAI Agliarulo
I Agliarulo
FMF Maddalena
F Maddalena
LSL Sisinni
L Sisinni
FEFranca Esposito
Franca Esposito
TNF receptor-associated protein 1 (TRAP1), the main mitochondrial member of the heat shock protein (HSP) 90 family, is induced in most tumor types and is involved in the regulation of proteostasis in the mitochondria of tumor cells through the control of folding and stability of selective proteins, such as Cyclophilin D and Sorcin. Notably, we have recently demonstrated that TRAP1 also interacts with the regulatory protein particle TBP7 in the endoplasmic reticulum (ER), where it is involved in a further extra-mitochondrial quality control of nuclear-encoded mitochondrial proteins through the regulation of their ubiquitination/degradation. Here we show that TRAP1 is involved in the translational control of cancer cells through an attenuation of global protein synthesis, as evidenced by an inverse correlation between TRAP1 expression and ubiquitination/degradation of nascent stress-protective client proteins. This study demonstrates for the first time that TRAP1 is associated with ribosomes and with several translation factors in colon carcinoma cells and, remarkably, is found co-upregulated with some components of the translational apparatus (eIF4A, eIF4E, eEF1A and eEF1G) in human colorectal cancers, with potential new opportunities for therapeutic intervention in humans. Moreover, TRAP1 regulates the rate of protein synthesis through the eIF2α pathway either under basal conditions or under stress, favoring the activation of GCN2 and PERK kinases, with consequent phosphorylation of eIF2α and attenuation of cap-dependent translation. This enhances the synthesis of selective stress-responsive proteins, such as the transcription factor ATF4 and its downstream effectors BiP/Grp78, and the cystine antiporter system xCT, thereby providing protection against ER stress, oxidative damage and nutrient deprivation. Accordingly, TRAP1 silencing sensitizes cells to apoptosis induced by novel antitumoral drugs that inhibit cap-dependent translation, such as ribavirin or 4EGI-1, and reduces the ability of cells to migrate through the pores of transwell filters. These new findings target the TRAP1 network in the development of novel anti-cancer strategies.

27 June 2014 in International Journal of Oncology
Verified
Journal Article
Closed access
MAMaria Rosaria Amoroso
Maria Rosaria Amoroso
DMDanilo Swann Matassa
Danilo Swann Matassa
LSLorenza Sisinni
Lorenza Sisinni
GLGiacomo Lettini
Giacomo Lettini
MLMatteo Landriscina
Matteo Landriscina
FEFranca Esposito
Franca Esposito
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

13 November 2014 in Cancer Research
Verified
Journal Article
Open access
PDF file
VCValentina Condelli
Valentina Condelli
APAnnamaria Piscazzi
Annamaria Piscazzi
LSLorenza Sisinni
Lorenza Sisinni
DMDanilo Swann Matassa
Danilo Swann Matassa
FMFrancesca Maddalena
Francesca Maddalena
MLMatteo Landriscina
Matteo Landriscina
Human BRAF-driven tumors are aggressive malignancies with poor clinical outcome and lack of sensitivity to therapies. TRAP1 is a HSP90 molecular chaperone deregulated in human tumors and responsible for specific features of cancer cells, i.e., protection from apoptosis, drug resistance, metabolic regulation, and protein quality control/ubiquitination. The hypothesis that TRAP1 plays a regulatory function on the BRAF pathway, arising from the observation that BRAF levels are decreased upon TRAP1 interference, was tested in human breast and colorectal carcinoma in vitro and in vivo. This study shows that TRAP1 is involved in the regulation of BRAF synthesis/ubiquitination, without affecting its stability. Indeed, BRAF synthesis is facilitated in a TRAP1-rich background, whereas increased ubiquitination occurs upon disruption of the TRAP1 network that correlates with decreased protein levels. Remarkably, BRAF downstream pathway is modulated by TRAP1 regulatory activity: indeed, TRAP1 silencing induces (i) ERK phosphorylation attenuation, (ii) cell-cycle inhibition with cell accumulation in G0–G1 and G2–M transitions, and (iii) extensive reprogramming of gene expression. Interestingly, a genome-wide profiling of TRAP1-knockdown cells identified cell growth and cell-cycle regulation as the most significant biofunctions controlled by the TRAP1 network. It is worth noting that TRAP1 regulation on BRAF is conserved in human colorectal carcinomas, with the two proteins being frequently coexpressed. Finally, the dual HSP90/TRAP1 inhibitor HSP990 showed activity against the TRAP1 network and high cytostatic potential in BRAF-mutated colorectal carcinoma cells. Therefore, this novel TRAP1 function represents an attractive therapeutic window to target dependency of BRAF-driven tumors on TRAP1 translational/quality control machinery. Cancer Res; 74(22); 6693–704. ©2014 AACR.

1 February 2009 in Journal of Molecular Biology
Verified
Journal Article
Closed access
APAlessandra Pesce
Alessandra Pesce
LTLiesbet Thijs
Liesbet Thijs
MNMarco Nardini
Marco Nardini
FDFilip Desmet
Filip Desmet
LSLorenza Sisinni
Lorenza Sisinni
SDSylvia Dewilde
Sylvia Dewilde